Embecta Corp. (EMBC) stock
EMBCNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends September 30
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 15/3080% below fair value
$6.15−0.10 (-1.60%)
Close on Nov 17, 2026Market cap $348.46MP/E 4.2Yield 9.76%
Embecta r&d expenses
Research and development expenses are spending on new products and technology.
Embecta's R&D Expenses for the twelve months ending Jun 30, 2026 was $20.20M, down 61.5% year over year. For fiscal 2025 it was $37.30M, down 52.7% from the year before. The highest annual figure on record is $85.20M in fiscal 2023.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $37.30M | -52.7% |
| FY2024 | Sep 30, 2024 | $78.80M | -7.5% |
| FY2023 | Sep 30, 2023 | $85.20M | +27.4% |
| FY2022 | Sep 30, 2022 | $66.90M | +5.7% |
| FY2021 | Sep 30, 2021 | $63.30M | +3.1% |
| FY2020 | Sep 30, 2020 | $61.40M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026CQ2 2026 | Jun 30, 2026 | $5.60M | +27.3% |
| Q2 FY2026CQ1 2026 | Mar 31, 2026 | $5.40M | -32.5% |
| Q1 FY2026CQ4 2025 | Dec 31, 2025 | $4.60M | -77.3% |
| Q4 FY2025CQ3 2025 | Sep 30, 2025 | $4.60M | -76.8% |
| Q3 FY2025CQ2 2025 | Jun 30, 2025 | $4.40M | -78.4% |
| Q2 FY2025CQ1 2025 | Mar 31, 2025 | $8.00M | -56.5% |
| Q1 FY2025CQ4 2024 | Dec 31, 2024 | $20.30M | +0.5% |
| Q4 FY2024CQ3 2024 | Sep 30, 2024 | $19.80M | -16.1% |
| Q3 FY2024CQ2 2024 | Jun 30, 2024 | $20.40M | -9.7% |
| Q2 FY2024CQ1 2024 | Mar 31, 2024 | $18.40M | -16.7% |
| Q1 FY2024CQ4 2023 | Dec 31, 2023 | $20.20M | +19.5% |
| Q4 FY2023CQ3 2023 | Sep 30, 2023 | $23.60M | +31.8% |
| Q3 FY2023CQ2 2023 | Jun 30, 2023 | $22.60M | +58.0% |
| Q2 FY2023CQ1 2023 | Mar 31, 2023 | $22.10M | +22.8% |
| Q1 FY2023CQ4 2022 | Dec 31, 2022 | $16.90M | +1.2% |
| Q4 FY2022CQ3 2022 | Sep 30, 2022 | $17.90M | -8.2% |
| Q3 FY2022CQ2 2022 | Jun 30, 2022 | $14.30M | -8.9% |
| Q2 FY2022CQ1 2022 | Mar 31, 2022 | $18.00M | +27.7% |
| Q1 FY2022CQ4 2021 | Dec 31, 2021 | $16.70M | +19.3% |
| Q4 FY2021CQ3 2021 | Sep 30, 2021 | $19.50M | – |
| Q3 FY2021CQ2 2021 | Jun 30, 2021 | $15.70M | – |
| Q2 FY2021CQ1 2021 | Mar 31, 2021 | $14.10M | – |
| Q1 FY2021CQ4 2020 | Dec 31, 2020 | $14.00M | – |
See a number that looks wrong?